Marché mondial de l’angiomyolipome – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché de l'angiomyolipome

Le marché mondial de l'angiomyolipome devrait connaître une croissance significative au cours de la période de prévision. Les marchés émergents et les investissements massifs dans la recherche et le développement sont les facteurs responsables de la croissance de ce marché. La croissance du marché de l'angiomyolipome a été renforcée par l'augmentation des cas d'angiomyolipome et l'augmentation des activités de recherche et développement menées par de nombreuses sociétés pharmaceutiques. Le COVID-19 a également eu un impact majeur sur la croissance du marché.

 Data Bridge Market Research analyse le taux de croissance du marché mondial de l'angiomyolipome au cours de la période de prévision 2022-2029. Le TCAC attendu du marché mondial de l'angiomyolipome a tendance à être d'environ 6,50 % au cours de la période de prévision mentionnée. En plus des informations sur le marché telles que la valeur marchande, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l'équipe de Data Bridge Market Research comprend également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Définition du marché

L'angiomyolipome est la tumeur rénale bénigne la plus courante, composée de vaisseaux sanguins, de cellules musculaires lisses et de cellules adipeuses. Il se forme sur le rein et altère sa fonction, ce qui conduit finalement à des maladies rénales chroniques et à l'hypertension.

Portée et segmentation du marché de l'angiomyolipome

Global Angiomyolipoma Market Dynamics

Drivers

• Increase in Geriatric Population

The geriatric population is expected to increase the patient population globally, which boots the global angiomyolipoma market in the forecast period. According to the WHO, the global elderly population is expected to reach around 2 billion by 2050 from 617 million in 2015. This boost the market growth.

• Rising Demand for Oral Drugs

Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.

Opportunities

• Rising Incidence of Angiomyolipomas

Angiomyolipomas (AMLs) are the most common benign renal tumour, with an incidence varying between 0.2% and 0.6% and a strong female domination. They occur as isolated entities in 80% of cases and thus is driving the market growth.

• Increasing Demand for Retail Pharmacies

The rise in the number of angiomyolipoma therapeutics delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

• Lack of skilled professionals

The lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global angiomyolipoma market over a forecast period.

• High Cost

The huge expenditure associated with global angiomyolipoma medications surely hamper the market growth.

This global angiomyolipoma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global angiomyolipoma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Angiomyolipoma Market      

Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business. Its long-term repercussions are expected to influence industry growth during the forecast period. Transition of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and delays in clinical trials.

In the post-pandemic era, the biotechnology and pharmaceutical industries are expected to witness a huge future growth due to the demand for vaccine and treatment drugs for COVID-19. Thus, this will leave a significant impact on the angiomyolipoma market.

Global Angiomyolipoma Market Scope

The global angiomyolipoma market is segmented on the basis of treatment type, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Medicines
• Surgery

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Angiomyolipoma Market Regional Analysis/Insights

The global angiomyolipoma market is analysed and market size insights and trends are provided by treatment type, distribution channel and end-user as referenced above.

The major countries covered in the global angiomyolipoma market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for angiomyolipoma market throughout the forecasted period owing to the global leaders in research and development activities and rise in patient assistance programs.

Asia-Pacific dominates the market due to the developing healthcare facilities, large number of generic manufacturer and rise in government initiatives and specialist communities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Angiomyolipoma Market Share Analysis

Le paysage concurrentiel du marché mondial de l'angiomyolipome fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché mondial de l'angiomyolipome

Les principaux acteurs opérant sur le marché mondial de l'angiomyolipome comprennent :

• Novartis SA (Suisse)
• Hikma Pharmaceuticals PLC (États-Unis)
• Endo International Inc (Irlande)
• Teva Pharmaceutical Industries Ltd (Israël)
• Glenmark Pharmaceuticals Ltd (Inde)
• Alkem Labs (Inde)
• Cipla Inc (Inde)
• Dr Reddy's Laboratories Ltd (Inde)
• NATCO Pharma Limited (Inde)

SKU-53545